A class of less toxic retinoids, called heteroarotinoids, was evaluated for their molecular mechanism of growth inhibition of two head and neck squamous cell carcinoma (HNSCC) cell lines SCC-2 and SCC-38. A series of 14 heteroarotinoids were screened for growth inhibition activity in vitro. The two most active compounds, one that contained an oxygen heteroatom (6) and the other a sulfur heteroatom (16), were evaluated in a xenograph model of tumor establishment in nude mice. Five days after subcutaneous injection of 10 7 SCC-38 cells, groups of 5 nu/nu mice were gavaged daily (5 days/week for 4 weeks) with 20 mg/kg/day of all-transretinoic acid (t-RA, 1), 10 mg/kg/day of 6, 10 mg/kg/day of 16, or sesame oil. After a few days, the dose of t-RA (1) was decreased to 10 mg/kg/day to alleviate the side effects of eczema and bone fracture. No significant toxic effects were observed in the heteroarotinoid groups. All three retinoids caused a statistically significant reduction in tumor size as determined by the Student t-test (P < 0.05). Complete tumor regression was noted in 3 of 5 mice treated with t-RA (1), 4 of 5 mice treated with 16, 1 of 5 mice treated with 6, and 1 of 5 mice treated with sesame oil. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to determine that the expression levels of RARR, RXRR, and RXR were similar in the two cell lines, while RAR expression was higher in SCC-2 over SCC-38, and RARγ expression was higher in SCC-38 over SCC-2. Receptor cotransfection assays in CV-1 cells demonstrated that 16 was a potent activator of both RAR and RXR receptors, while 6 was selective for the RXR receptors. Transient cotransfection assays in CV-1 cells using an AP-1 responsive reporter plasmid demonstrated that t-RA (1), 6, and 16 each inhibited AP-1-driven transcription in this cell line. In conclusion, the growth inhibition activity of the RXR-selective 6 and the more potent growth inhibition activity of the RAR/RXR pan-agonist 16 implicate both RARs and RXRs in the molecular mechanism of retinoid growth inhibition. Moreover, the chemoprevention activity and the lack of toxicity of heteroarotinoids demonstrate their clinical potential in head and neck cancer chemoprevention.
Introduction
Retinoids have been known to elicit useful pharmacological responses in a variety of disorders. 1 Activities of endogenous retinoids such as trans-retinoic acid (t-RA, 1), 9-cis-retinoic acid (9-c-RA, 2), and 13-cis-retinoic acid (13-c-RA, 3) are well-known in cancer therapy, although all have some toxic characteristics. 2 The synthetic retinoid 4-(hydroxyphenyl)retinamide (4, 4-HPR), currently under clinical investigation, is also known to possess some undesirable properties such as night blindness, although it appears to be dose-dependent and reversible. 3 Certain heteroarotinoids have demonstrated anticancer activity as well as low toxicity. [4] [5] [6] [7] [8] We now report the growth inhibitory activity of a variety of heteroarotinoids 5-19 (Chart 1) against head and neck squamous cell carcinoma (HNSCC) cell lines, SCC-2 and SCC-38. The heteroarotinoids possess a range of flexibility in terms of the linking groups attached to the aryl ring and, in most cases, between two aryl rings. It was reasoned that such flexibility might better allow accommodation of the molecule in the receptor site and therefore lead to an activated complex of ligandreceptor. The area of ligand-receptor binding has been reviewed. 9 Head and neck cancers often arise from a field of epithelial injury caused by carcinogens in tobacco smoke which, in turn, leads to multiple premalignant lesions and the risk of primary and second primary tumor formation. 10, 11 Retinoids have been shown to reverse oral premalignant lesions and prevent second primaries in patients treated for head and neck cancers. The use of retinoids for the prevention and treatment of head and neck cancers was inspired by the observations that vitamin A deficiency caused keratinizing squamous metaplasia in mucociliary epithelium and that replenishment of retinoids restored normal epithelial differentiation. 12, 13 Leukoplakia and erythroplakia are premalignant head and neck mucosal lesions. Several studies have attempted to use retinoids to prevent or reverse these lesions back to normal mucosa in highrisk patients. In a low-dose experiment that showed minimal toxicity to the patients, the natural retinoid 13-c-RA (3) was found to be superior to -carotene in reducing the rate of oral leukoplakia progression. 14 The synthetic retinoid 4-HPR (4) has been shown to decrease relapses and new localizations of surgically treated oral leukoplakia from 30% to 6%. 15 Many head and neck epithelial malignancies are multifocal, and the development of a second primary tumor either during treatment or after successful treatment for a primary tumor occurs at a rate of 4-7%/ year. 16 A population of these patients had significant reductions in development of second primary tumors when treated with 13-c-RA (3) for a median follow-up of 54 months. 17 Despite these encouraging results, a large number of relapses have been detected upon cessation of certain agents, and there have been numerous side effects, especially at high doses. These side effects include mucocutaneous dryness, dermatitis, conjunctivitis, photodermatosis, impaired night vision, hypertriglyceridemia, and transient increases in serum liver function enzymes. Efforts to prevent relapses and to reduce toxicity have included co-treatment with R-tocopherol and the development of synthetic retinoids. 7, 18 Prior to clinical application, the chemoprevention activities of retinoids are usually evaluated against HNSCC cell lines in vitro and in animal models in vivo. Although vitamin A is the least toxic of the natural retinoids, it is also the weakest inhibitor of growth in HNSCC cell lines in vitro and in xenograph growth in vivo, followed by 13-c-RA (3). [19] [20] [21] [22] [23] [24] The reduced toxicity of certain heteroarotinoids 7 prompted an evaluation in the present study to determine if such heterocycles inhibited the growth of HNSCC cell lines in vitro and in vivo and to explore the molecular mechanism of action of such agents.
ined for useful activity 25 and even for RARR selectivity, 26 no record of the use of a C(O)-N-methoxy linker could be found in the literature. The excess bulk of this group was considered as altering the rotational barrier of the C-N bond and thereby possibly influencing receptor binding and activation.
Generation of the acid chloride from known 20 8 and subsequent treatment with the appropriate hydroxylamine as shown gave 21 (Scheme 1). O-Methylation proceeded under mild conditions to yield 7 (48%).
Creating and assessing ester 8 for useful activity was considered a test of the influence on activity by flanking methyl groups of the aryl ring with respect to freedom of rotation of the internal ester linkage. In addition, it is known 5, 7 that alkyl groups adjacent to the heteroatom have a positive influence on biological activity. Thus, ester 8 possesses both such features. Excess methylmagnesium bromide added to known 22 27 in boiling ether over 48 h led to lactol 23 (Scheme 2). Dehydration of 23 under standard conditions yielded ether 24. Direct esterification of 24 gave new ester 8 (50%) which was purified by chromatography. Surprisingly, when 22 was treated with the same excess of methyl Grignard reagent as used to obtain 23, but in THF, ether 25 (76%) formed (Scheme 3). Perhaps the much longer reaction time was significant, but the solvent was found to be important as well. Esterification of 25 under the usual conditions produced the target ester ether 9 (52%). This heteroarotinoid 9 possessed the geminal methyl flanking group that enhanced activity in several assays in related systems which contained more rigid linking groups attached to the aryl ring. 5 Consequently, an assessment could be made of the alteration in activity between 8 and 9.
Retaining the flexible ester linkage between the two aryl rings was desirable in 10. In part, the rationale for 10 was based on the strong activity of (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB), although it is very toxic. 7 The incorporation of an oxygen atom into system 10 might reduce toxicity sufficiently to be tolerable and yet retain useful activity. Dimethylation of 26 as shown was facile and gave 27 in high yield (84%) (Scheme 4). Base-catalyzed hydrolysis of 27 led to acid 28 (69%), a reported compound 28 but not previously well-characterized. Reduction of 28 to 29 was straightforward, and alcohol 29 was cyclized with the incorporation of an acetone unit to yield ether 30 (75%). Acetylation of 30 proved more difficult than anticipated, but the use of H 3 CNO 2 with AlCl 3 and AcCl was successful and gave 31 (51%) without cleavage of the methoxy ether group. Oxidative cleavage of the acetyl group in 31 to give acid 32 gave only a modest yield (21%) due to side reactions.
The use of a combination of LiOCl/Clorox was ultimately successful. Esterification of 32 required a long reaction time to obtain 10, apparently due to the increased steric hindrance around the carbonyl group of 32.
In view of the known toxicity of TTNPB, 7 the synthesis of the close analogue 11 (Scheme 5) would also serve as a model for comparison of activity with that of heteroarotinoid 10. Acetylation of known 29 33 also was demanding in terms of avoiding or minimizing cleavage of the ether linkage in 30. Using the conditions outlined resulted in the generation of 34 (75%). As with the conversion of 31 to 32, generation of acid 35 from ketone 34 was slow because of hindrance, although 35 was isolated in moderate yield (44%). Esterification of 35 to produce 11 (67%) required a long reaction time as anticipated.
The unusual heteroarotinoid 13 was selected for inclusion in the study since it possessed a rigid long side chain and contained two heteroatoms in the fused ring unit. Other heteroarotinoids with long side chains had exhibited strong activity in several assays. 5, 6 The influence of two heteroatoms could also be assessed. The addition of a nearly 3-fold excess of vinylmagnesium bromide to commercial 36 resulted in essentially a quantitative yield of slightly crude 37 (Scheme 6). Conversion of the vinyl alcohol 37 to the phosphonium salt 38 (85%) was effected by conditions previously developed. 5, 7 Generation of the Wittig reagent of 38 as shown was followed by the addition of ethyl 3-methyl-4-oxocrotonate in a normal condensation to provide heteroarotinoid 13, albeit in modest yield (28.8%).
The flexible heteroarotinoid 16 could be obtained via the conversion of 39 f 40 f 41 f 16 as illustrated (Scheme 7). The nitration of known 5 39 afforded the 6-isomer 40 in modest yield (27%) since other nitrated products appeared to have formed. Reduction of the nitro group in 40 to the amino function in 41 (50%) progressed reasonably well under mild conditions. NAcylation of 41 with the acid chloride shown produced the target 16 (72%), again under quite mild conditions. Biology. 1. In Vitro Growth Inhibition Screen. A series of retinoids were screened for growth inhibition activity in the SCC-2 and SCC-38 HNSCC cell lines. The activities of 14 heteroarotinoids containing a sulfur heteroatom (14) (15) (16) , an oxygen heteroatom (5-10, 12, 13), or a nitrogen heteroatom (17) (18) (19) , as well as a structurally related arotinoid (11) void of a heteroatom, were compared to that of 9-c-RA (2) ( Table 1) . Although most of the compounds inhibited growth, some of them stimulated growth. Three of the compounds with oxygen heteroatoms (5, 8, 9) had opposite effects in the two cell lines. The Student t-test was used to demonstrate that there were no statistically significant differences between the responses of the two cell lines to the entire set of retinoids (P > 0.05) or between the activities of groups with different types of heteroatoms (P > 0.05). The oxygen heteroarotinoid 6 and sulfur heteroarotinoid 16 were the most active in both cell lines and were therefore chosen for evaluation in a xenograft model.
2. Xenograft Model. The 6 and 16 compounds were evaluated for biological activity in a xenograft nude mouse model. Athymic nu/nu mice were injected subcutaneously with 10 7 SCC-2 or SCC-38 cells. The effects of retinoids in mice injected with SCC-2 cells could not be evaluated because these mice developed very large tumors and died rapidly of disease (data not shown). Mice injected with SCC-38, however, developed stable tumors and survived the duration of the month-long experiment. Mice bearing SCC-38 xenografts were arbitrarily divided into 4 treatment groups of 5 mice each and were gavaged with 0.1 mL of sesame oil containing either 20 mg/kg/day of t-RA (1), 10 mg/kg/ day of 6, 10 mg/kg/day of 16, or no drug control. After 1 week of treatment, the dose of t-RA (1) was decreased to 10 mg/kg/day due to excessive eczema and bone fractures in this group of mice. These toxicities were not evident in the other three treatment groups. There was no significant difference in the animal weights between the treatment groups ( Figure 1, panel A) .
Tumors developed from the SCC-38 cell line underwent a reduction in volume during days 9-14, followed by a stabilization of tumor size (Figure 1, panels B-D) . The tumors in the groups treated with t-RA (1) and 16 stabilized starting on days 12 and 14, respectively, at sizes that were significantly smaller than the tumors in the control group (P < 0.05, t-test), which were also stable during this period. The sizes of the tumors in the group treated with 6 were not significantly smaller than the tumors of the control group until day 26 (P <0.05, t-test). The last day of tumor measurements demonstrated growth in the control group compared to continued stabilization or further reduction in the treatment groups. The average tumor volumes of the four treatment groups were significantly different from each other after day 23 as determined by ANOVA (P < 0.05).
Complete tumor regression was observed in 3 of 5 mice treated with t-RA (1), 4 of 5 mice treated with 16, and 1 of 5 mice treated with 6. In the control group, 1 of 5 sesame oil-treated mice had complete tumor regression.
3. Receptor Expression. Retinoids regulate gene expression through two classes of nuclear retinoic acid receptors, RAR and RXR, each of which have three isoforms labeled R, , and γ. 9 The expression patterns of retinoic acid receptors in SCC-2 and SCC-38 were evaluated by reverse transcriptase polymerase chain reaction (RT-PCR). Both cell lines expressed RARR, RXRR, and RXR at similar levels ( Figure 2 ). The intensities of the actin control bands for each cell line were similar, but the intensities of the RAR and RARγ bands for each cell line varied, indicating that SCC-2 expressed higher levels of RAR in comparison to SCC-38 and that SCC-38 expressed higher levels of RARγ in comparison to SCC-2.
4. Nuclear Retinoid Receptor Activation. While t-RA (1) and arotinoid compounds only activate the RAR receptors, 9-c-RA (2) and some heteroarotinoids activate both RAR and RXR receptors. 9 To determine the specificity of retinoic acid receptor activation by 6 and 16 cotransfection assays using the RAR RARE-tk-CAT reporter plasmid were performed. All six nuclear receptors were activated by 6 and 16 in a dose-responsive manner. The concentration that induced half-maximal activity (EC 50 value) was derived as a measure of receptor potency, and the maximal activity relative to 9-c-RA (2) was derived as a measure of efficacy for each receptor (Table 2) . Heteroarotinoid 16 was a potent activator of all six receptors, while 6 was selective for the RXR receptors. Although the efficacy of RAR activation by 6 ranged from 24-58% of the activation by 9-c-RA (2), the greater than 10 000 nM potencies demonstrate that the concentrations needed to achieve this activation were above pharmacologically obtainable levels.
5. Anti-AP-1 Activity. The ligand-bound retinoic acid receptors have been shown to repress transcriptional activation by AP-1 transcription factors. 30, 31 This anti-AP-1 activity has been implicated in the mechanism of growth inhibition. 32, 33 The ability of t-RA (1), 9-c-RA (2), 6, and 16 to repress AP-1-driven transcription was evaluated using transient transfection assays of an AP-1-driven reporter plasmid into SCC-2 cultures ( Figure  3 ). All the retinoids repressed AP-1 activity, and 16 exhibited the greatest repression. Similar experiments using SCC-38 cultures could not be performed due to the poor transfection efficiency of this line.
Conclusions
In this report, the potential of certain heteroarotinoids for chemoprevention of head and neck cancers was confirmed by growth inhibition of HNSCC cell lines in vitro and prevention of tumor establishment in a xenograph nude mouse model in vivo. The SCC-38 xenograph tumors in this study exhibited a reduction during days 9-14, followed by a stabilization of tumor size ( Figure 1 ). The curves in all four groups were remarkably similar for days 9-14, suggesting that this initial regression in size was due to factors intrinsic to the xenograph model such as absorption of diluent and nonviable tumor cells and resolution of the host's inflammatory response to tumor injection. The last tumor measurement in the control group, however, demonstrated significant growth compared to continued stabilization or further reduction in the treatment groups. This implies that the model is reflective of tumor establishment rather than tumor growth. Establishment of tumor implants appears to have occurred over the initial 28 days following injection, while growth of the established tumors did not occur until after day 28. The efficacy of the two heteroarotinoids in prevention of the establishment of SCC-38 xenograph tumors is indicated by the significant decrease in size of the tumors in the groups treated with 6 and 16. The complete regression of 4 out of 5 xenograph tumors in the group treated with 16, in comparison to 1 out of 5 in the control group, is a more convincing demonstration of heteroarotinoid chemoprevention activity.
The molecular mechanism of this growth inhibition most likely involves the regulation of gene expression through the nuclear retinoic acid receptors. In support of this hypothesis, the use of t-RA (1) to treat squamous cell carcinoma HNSCC cell lines resulted in decreased expression of two genes that are associated with increased proliferation and that are commonly overex- pressed in head and neck cancers, namely the transforming growth factor R (TGF-R) and the epidermal growth factor receptor (EGF-R). 34 The growth inhibition activities of compounds, such as t-RA (1), that activate all RAR receptors are not likely to be strongly affected by alterations in the pattern of receptor expression. In agreement with this suggestion, a study using a panel of six HNSCC cell lines revealed that receptor expression patterns were unrelated to a response to t-RA (1) treatment. 21 In contrast, the activities of receptorselective retinoids can be affected by the receptor expression patterns in head and neck lesions. An investigation of premalignant, dysplastic, and malignant head and neck cancers found that RAR expression was suppressed in more than 50% of all lesions. 23 However, RARγ expression was not suppressed and has been implicated in squamous differentiation and t-RA response in HNSCC. 35, 36 The role of RARγ in the mechanism of retinoid growth inhibition in HNSCC cell lines has been illustrated by the use of sense and antisense RARγ expression in the SqCC/Y1 line. 36 While t-RA (1) treatment and sense RARγ expression caused growth inhibition, AP-1 repression and decreased expression of EGF-R and of squamous differentiation markers, anti-sense RARγ, antagonized these activities. Therefore, the potencies of RAR and RARγ activation by 16 (EC 50 's of 1004 and 152 nM, respectively) are amenable to use against head and neck lesions that have decreased expression of RAR and consistent expression of functional RARγ. Both SCC-2 and SCC-38 cell lines evaluated in this study expressed all of the human RAR and RXR nuclear retinoic acid receptors and are therefore susceptible to all retinoic acid receptor-selective compounds. The potent growth inhibition activity of 6, which is selective for the RXR receptors, suggests that RXR activation is sufficient for growth inhibition of SCC-2 and SCC-38. The greater activity of 16, which is an RAR/RXR panagonist, indicates that RARs also contribute to the mechanism of growth inhibition by heteroarotinoids. Additive and synergistic activity of RAR-and RXRselective retinoids has been noted in other cell lines in vitro. 37 The inhibition of HNSCC xenograph tumor growth by an RAR-selective retinoid, observed by others, 38 and by RXR-selective retinoid 6, in this study, demonstrates that either RAR or RXR activation is sufficient for growth inhibition. The more potent activity of RAR/RXR pan-agonist 16 suggests that activation of both RAR and RXR receptors is also complimentary in vivo.
Since all of the retinoids used in the animal model repressed AP-1-driven transcription to similar extents, the contribution of anti-AP-1 activity to the mechanism of growth inhibition cannot be ruled out. Although the most biologically active heteroarotinoid 16 exhibited the greatest repression of AP-1 activity, it was also the most active RARE transactivator and, therefore, cannot be used to differentiate the two retinoid activities. It is most likely, however, that both anti-AP-1 and RARE transactivation activities are involved in the mechanism of retinoid growth inhibition to different degrees, depending upon the inner cellular environment. A series of heteroarotinoids are currently being investigated for selected anti-AP-1 activity in the absence of RARE transactivation activity. These types of selective compounds can be used to evaluate the role of AP-1 repression in the mechanism of growth inhibition.
In conclusion, the growth inhibitory activity of RXRselective 6 and the more potent growth inhibition activity of RAR/RXR pan-agonist 16 implicate both RARs and RXRs in the molecular mechanism of retinoid growth inhibition of HNSCC cell lines. Both agents exhibit anti-AP1 activity that may contribute to the mechanism of action. Moreover, the chemoprevention activity and lack of toxicity of heteroarotinoids demonstrate their clinical potential in head and neck cancer chemoprevention.
Experimental Section
Chemical Methods. General. IR spectra were recorded on a Perkin-Elmer 2000 FT-IR as films or as KBr pellets. GC-MS data were obtained from a HP G1800A GCD System GC electron ionization detector. FAB MS experiments were performed on a VG ZAB-2SE HRMS unit, while EI MS experiments were accomplished with an HP GC-MS ENGINE model 5989B unit. All 1 H and 13 C NMR spectra were taken on a Varian Inova 400 MHz or Varian XL-400 MHz BB spectrometer operating at 399.99 and 100.0 Hz, respectively, and signals were referenced to TMS. Melting points were determined with a Thomas-Hoover melting point apparatus and were uncorrected. Syntheses were executed, unless otherwise indicated, under an atmosphere of N 2. Elemental analyses were performed by Galbraith Laboratories, Knoxville, TN, or by Atlantic Microlab, Inc., Norcross, GA. All chromatography was performed with the chromatotron unless otherwise noted and utilized silica gel, pF 254 containing gypsum (EM Science).
Heteroarotinoids 39 were prepared by known methods. Although the intermediates and final products appeared to be relatively stable in light, precautions were taken to minimize exposure to any light source and to the atmosphere. In the purified state, all materials were stored in the cold and dark for indefinite periods without significant decomposition.
Biological Methods. Cell Lines. The SCC-2 cell line was derived from a patient with T1,N0 well-differentiated squamous cell carcinoma of the mandibular alveolus. The SCC-38 cell line was derived from a patient with a T2,N2a moderately well-differentiated squamous cell carcinoma of the base of the tongue. Cells were maintained in Eagles minimal essential media (MEM) containing Earle's salts and L-glutamine, supplemented with nonessential amino acids, antibiotic-antimycotic, sodium pyruvate, and 10% fetal bovine serum (FBS) in 95% air-5% CO2. Only lots of FBS that had negligible quantities of retinoic acid as determined by HPLC (<10 -8 M) were used.
Retinoids. All heteroarotinoids (5-10, 12-19), arotinoid 11, t-RA (1; Sigma Chemical Co., St. Louis, MO), and 9-c-RA (2; Bio-Mol, Plymouth Meeting, PA) were dissolved in dimethyl sulfoxide (DMSO) for in vitro studies or highly refined sesame oil (Croda, Inc., Mill Hall, PA) for in vivo studies, were protected from light, and were stored at -70°C. For the tissue culture studies, retinoids were added from 1000X stocks, achieving a final concentration of 0.01% DMSO in the culture medium. For the animal studies, the retinoids were dissolved at a concentration equal to the daily dose of 0.1 mL of sesame oil.
Methyl N-(4-Methoxyoxophenyl)-4,4-dimethyl-3,4-dihydro-2H-benzo[b]pyran-6-ylhydroxamate (7). A mixture of powdered KOH (0.022 g, 0.38 mmol) and DMSO (1 mL) was stirred for 5 min, and then ester 21 (0.090 g, 0.25 mmol) was added, followed by an immediate addition of H 3C-I (0.031 mL, 0.51 mmol) with stirring. After stirring for 0.5 h, the resulting mixture was poured into H2O (10 mL). Extraction (H2CCl2, 3 × 10 mL) of the aqueous layer and combining the extracts gave a solution which was washed with water and brine. After drying (MgSO4), the solution was evaporated to a colorless solid which was recrystallized (hexanes:EtOAc the filtrate was cooled (0°C) overnight and filtered again. Evaporation of the solvent gave a heavy oil which was subjected to chromatography (H2CCl2 
Ethyl (2E,4E,6E)-7-(2,3-Dihydro-1,4-benzodioxan-6-yl)-3-methyl-2,4,6-octatrienoate (13).
To a stirred suspenion of 38 (4 g, 7.53 mmol) in dry ether (40 mL) was added dropwise n-BuLi (14 mL, 0.906 M, 21.7 mmol in hexanes) over 5 min. The resulting dark red solution was stirred for 0.5 h, and then ethyl 3-methyl-4-oxocrotonate (l.3 mL, 9.15 mmol) in dry ether (10 mL) was added dropwise. After 10 h of stirring at rt, the solution was diluted (hexanes, 100 mL), filtered, and evaporated to a light yellow oil. Crystals formed upon standing and were recrystallized (absolute ethanol) to give 13 (0.683 g, 28 
Methyl 4-[(2,3-Dihydro-2,2,4,4-tetramethyl-2H-1-benzothiopyran-6-yl)carbamoyl]benzoate (16).
To a solution of amine 41 (1.6 g, 7.32 mmol) in dry benzene (90 mL) and pyridine (9.2 mL) at rt was added slowly, with stirring, freshly made methyl monoterephthaloyl chloride (2.20 g, 10.84 mmol). After stirring for 12 h (rt), the mixture was poured into water, and the resulting mixture was extracted (EtOAc, 4 × 200 mL). The combined extracts were washed with 6 N HCl (4 × 50 mL), H 2O (3 × 400 mL), saturated NaHCO3 (2 × 400 mL), H2O (50 mL), and brine (200 mL). The dried (Na2SO4) organic solution was evaporated to a light yellow solid which was purified via chromatography over silica gel (hexane:EtOAc: Et2NH, 74 a The efficacy was derived by dividing the maximal activity induced by 6 or 16 by the maximal activity induced by 9-c-RA (2). All compounds exhibited maximal activity at a concentration of 10 µM. The maximal activity induced by 10 µM 9-c-RA (2) was 4.2-fold induction for RARR, 2.6-fold for RAR , 2.4-fold for RARγ, 3.8-fold for RXRR, 4.0-fold for RXR , and 3.7-fold for RXRγ. [HOCdO]; MS (EI) calcd for C22H25O3SN [M + ] 383.1555, found 381.1552. Anal. (C22H25O3SN) C, H, N. 7 (0.300 g, 1.40 mmol) and thionyl chloride (15 mL) were stirred at rt for 16 h. Excess thionyl chloride was evaporated under aspirator pressure, and the residual acid choride (an oil) was further dried under higher vacuum (∼2 mmHg) to remove traces of thionyl chloride. The hydroxylamine (0.253 g, 1.40 mmol) was dissolved in THF (10 mL), and then NaHCO3 (0.176 g, 2.1 mmol) was added at rt. The above acid chloride was dissolved in a minimum of dry ether and then was added slowly to the solution of the hydroxylamine at 0°C. The resulting mixture was stirred (rt) for 18 2,3-Dihydro-2,6-dihydroxy-2,4,4,5,7-pentamethyl-2H-benzopyran (23). To a solution of 1.50 mL (4.50 mmol) of 3 M methylmagnesium bromide in ether (5 mL) was added (rt) the coumarol 22 27 (0.100 g, 0.45 mmol) in ether (5 mL). The resulting solution was stirred for 48 h (rt). After the solution was allowed to cool to rt, a saturated solution (∼10 mL) of aqueous H4NCl was added slowly. Separation of the layers was followed by extraction (ether, 3 × 10 mL) of the organic layer to give extracts which were washed with water and brine. After drying (MgSO4), the solution was evaporated to give the lactol 23 as a colorless solid (0.57 g, 54%): mp 105. 5 6-Hydroxy-2,4,4,5,7-pentamethyl-4H-1-benzopyran (24). A mixture of lactol 23 (0.100 g, 0.42 mmol), a catalytic amount of p-toluenesulfonic acid (0.025 g), 4A molecular sieves (1.0 g), and toluene was boiled for 2 h. After cooling to rt and filtering, the filtrate was washed with a saturated solution of NaHCO3 (∼10 mL) and then with brine. The dried (Na2SO4) organic solution was evaporated to yield 24 (0.082 g, 89%) as a light yellow oil: IR (neat) (25) . To a solution of methylmagnesium bromide (1.50 mL, 34.50 mmol, 3 M) in THF (5 mL) was added coumarol 22 27 (0.100 g, 0.45 mmol) in THF (5 mL) at rt. The resulting solution was stirred for 4 days at reflux and was then allowed to cool. Saturated aqueous H4NCl was added, and two layers separated. Extraction (ether, 3 × 10 mL) of the aqueous layer and combining the extracts gave an organic solution which was washed with H2O and brine. The dried (MgSO4) solution was evaporated to a colorless solid (0.086 g, 76%) of 25: mp 62. 5 
N-(4-Methoxyoxophenyl)-4,4-dimethyl-3,4-dihydro-2H-benzo[b]pyran-6-ylhydroxamic Acid (21). Acid 20
2-(3-Methoxyphenyl)-2-methylpropanenitrile (27). An orange mixture of KOH (20.0 g. 0.356 mol), triethylbenzylammonium bromide (TEBA; 2.0 g, 7.46 mmol), and (3-methoxyphenyl)acetonitrile (26; 20.0 g, 0.135 mol) was heated at 80°C for 0.5 h. Methyl iodide (11.50 g, 0.810 mol) was added slowly over 2 h, and the resulting yellow mixture was heated (80°C) for 1 h. Additional KOH (20.0 g, 0.356 mol) was then added along with TEBA (2.0 g, 7.46 mmol), and the new mixture was stirred vigorously for 0.5 h. Methyl iodide (11.50 g, 0.081 mol) was added over 1 h, and the resulting mixture was stirred with heating (80-100°C) for 5 h. After cooling to rt, the reaction mixture was extracted (toluene, 5 mL). The combined organic extracts were washed with water and brine and then dried (MgSO 4). Evaporation of the solvent gave an oil (3.8 g, 84%) which was vacuum distilled (100-101°C/∼2 mmHg) to a colorless oil (13.4 g, 57%) 
2-(3-Methoxyphenyl)-2-methylpropanoic Acid (28).
A mixture of 27 (3.8 g, 0.0217 mol), KOH (5.00 g, 0.089 mol), diethylene glycol (30 mL), and water (5 mL) were heated at 130-140°C for 3 days and turned brown. After cooling to rt, the solution was poured into cold water. Extraction (benzene, 8 × 40 mL) of the aqueous layer followed, and then the residual aqueous layer was made acidic (concd HCl, pH ∼ 3). The new aqueous layer was extracted (ether, 4 × 30 mL), and the combined extracts were dried (MgSO 4). Evaporation of the solvent gave a yellow solid which recrystallized (hexane) to a white solid 28 (3.81 g, 69%): mp 79-80°C (lit. 28 
mp 80-81.5°C
). Since spectral data were scarce on 28, the following data were taken: IR (KBr) 3434-2538 (CO2H), 1702 (CdO) cm 2-(3-Methoxyphenyl)-2-methyl-1-propanol (29). To a mixture of LiAlH4 (2.23 g, 58.9 mmol) in dry THF (19 mL) was added dropwise acid 28 (3.81 g, 19.6 mmol) in dry THF (5 mL) over 0.5 h. After being heated at reflux (48 h), the resulting mixture was allowed to cool to rt and was then treated cautiously with ethanol/water to destroy residual LiAlH 4. A white solid formed and was filtered, and the remaining aqueous layer was extracted (ether, 5 × 30 mL). The combined extracts were washed with brine, dried (MgSO4), and evaporated to a colorless oil 29 (2. 6 mmol), acetone (30 mL), and concd HCl (10 mL) was heated and stirred at 45-50°C for 2 h and at rt for 12 h. The deep yellow solution was allowed to cool to rt and was then poured into ice-water. Two layers were separated, and the organic layer was extracted (ether, 5 × 20 mL). The combined extracts were washed with water (30 mL), saturated NaHCO 3 (30 mL), and brine and then was dried (MgSO4). Evaporation of the solvent gave a colorless oil 30 (0.92 g, 75%) which was used directly to prepare 31. Spectral data for 30 were as follows was added very slowly and portionwise AlCl3 (1.33 g, 10.0 mmol) over 1 h. The resulting brown mixture was stirred at rt for 24 h and was then poured cautiously into ice-water (50 mL). Dilute HCl (2 M, ∼5 mL) was added cautiously to destroy residual AlCl3. The layers were separated, the aqueous layer was extracted (H2CCl2, 3 × 10 mL), and the combined organic extractssoriginal layer were washed with H2O (20 mL), saturated aqueous NaHCO3 (25 mL), and brine. Evaporation of the solvent gave a solid which was by purified by chromatography (H2CCl2) and yielded a colorless solid 31 (0.562 g, 51%): mp 115-117°C; IR (KBr) 1662 (CdO) cm 40 The resulting light yellow solution was boiled (24 h) and then allowed to cool to rt. The basic solution was extracted (ether, 3 × 15 mL), and the combined extracts were washed with water (10 mL) and brine and then were dried (MgSO4). The original aqueous layer was acidified (2 M HCl, 10 mL, ∼pH 3) and then extracted (ether, 4 × 20 mL). The combined organic layers were washed with water (20 mL) and brine and then dried (MgSO4 32 (0.050 g, 0.23 mmol), acetyl chloride (0.049 g, 0.69 mmol), and H3CNO2 (5 mL) was added slowly and portionwise AlCl3 (0.092 g, 28.9 mmol) over 1 h. After stirring at rt (4 h), the brown solution was poured into ice-water (10 mL). Two layers were separated, and the aqueous layer was extracted (ether, 2 × 10 mL). The combined organic layers were washed with H2O (20 mL), saturated aqueous NaHCO3 (15 mL), and brine. After drying (MgSO4) and evaporation of the solvent from the solution, ketone 34 (0.045 g, 75%) was obtained as a light yellow solid: mp 96-98°C; IR (KBr) 1664 cm [40 g LiOCl (Bioguard), 80 mL Clorox], and 95% ethanol (45 mL) was boiled for 24 h and then allowed to cool to rt. An aqueous solution of Na2S2O5 (25%, 35 mL) was slowly added to the reaction mixture which was then acidified with 6 M HCl (10 mL, pH ∼ 3). Extraction (ether, 4 × 20 mL) of this mixture and then washing of the combined extracts with H2O (20 mL) and brine gave a new solution which was dried (MgSO4 [3-(2,3-Dihydro-1,4-benzdioxan-6-yl)-2-buten-1-yl]triphenylphosphonium Bromide (38) . To a stirred suspension of Ph3P‚HBr (2.61 g, 4.92 mmol) in dry methanol (20 mL) was added dropwise alcohol 37 (1.01 g, 4.92 mmol) in dry methanol (30 mL) over 10 min at rt under N2. After stirring at rt for 10 h, the suspension was concentrated to about 5 mL and was then transferred to a large beaker. Dry ether was added slowly with stirring to complete the precipitation. Filtration gave a solid which was washed (dry ether) and then was dissolved in dry methanol (∼15 mL). Ether was added to cloudiness, and the resulting mixture was chilled in the freezer. Filtration and drying the solid gave fine, white crystals of 38 (2. 22 5 (5.13 g, 24.8 mmol) in freshly distilled Ac2O (5 mL) at 0°C was added slowly a mixture of cold, concd HNO3 (3.54 mL) and Ac2O (9 mL) over 10 min. After being stirred for 2 h, the reaction mixture was poured into a solution of saturated, aqueous NaHCO3. Extraction (H2CCl2, 3 × 40 mL) of the water layer and combining the extracts and organic layer gave a solution which was washed with water and brine and then was dried (Na2SO4). Evaporation of the solvent gave a solid which was recrystallized (hexane) to yield 40 (1. 6 2,2,4,4-Tetramethyl-6-aminothiochroman (41). To chroman 40 (0.800 g, 3.18 mmol) in acetic acid (29 mL) and water (6 mL) was added dropwise with stirring TiCl3/HCl (33.00 g, 21.39 mmol). After stirring for 2 h (rt), the reaction mixtrure was cooled (0°C), and NaOH (30%, 130 mL) was added slowly. Extractions (EtOAc, 4 × 35 mL, and H2CCl2, 2 × 40 mL) of the mixture followed, and combining the extracts and organic layer gave a solution which was washed with H2O and saturated NaHCO3 (2 × 50 mL). The dried (Na2SO4) solution was evaporated to an oil which was separated via chromatography over silica gel (hexane:H2CCl2 In Vitro Growth Inhibition. Cultures were plated with 96-well microtiter plates in volumes of 150 µL at a concentration of 2500 cells/well. The next day, retinoids were added at 4X concentrations in 50 µL of media resulting in 10 -9 , 10 -8 , 10 -7 , 10 -6 , and 10 -5 M final concentrations of each retinoid. Control cultures were treated with the same volume of DMSO. After 3 days of treatment, the cell density in each well was determined by fixing the cells in trichloroacetic acid and staining the cytoplastic proteins with sulforhodamine B (SRB). After rinsing, the SRB was solubilized in TrisHCl, and the optical density of each culture was determined with a MR600 microtiterplate reader. Each experiment was performed in triplicate, and the three values for each treatment were averaged. The average OD of the treated cultures was divided by that of the control cultures treated with solvent alone. To determine the percent growth inhibition, this ratio was subtracted from 1 and multiplied by 100.
In Vivo Tumor Xenographs. Cells in log phase growth were harvested by trypsinization, resuspended in MEM culture medium, and centrifuged at 3000 rpm for 10 min. The pellets were resuspended in MEM culture medium at a concentration of 1 × 10 7 cells/mL before implantation into mice. Five-week old female athymic nu/nu mice (Harlan Sprague-Dawley, Indianapolis, IN) were housed in a laminar flow room under sterile conditions at 83-85°F. The mice were quarantined for 1 week prior to the beginning of the study and were allowed access to autoclaved food (Purina 5001 mouse/rat sterilizable diet, St. Louis, MO) and water ad libitum. Animals were injected with 1 × 10 7 cells into the right scapular region with a 24-gauge needle/1 cm 3 tuberculin syringe (Becton Dickinson, Rutherford, NJ). Twenty-four hours after tumor implantation, animals were randomized into 4 treatment groups of 5 animals each. Retinoids were administered daily po beginning 5 days after tumor implantation with a 20-gauge intragastric feeding tube (Popper & Sons, New Hyde Park, NY), 5 days/week, at doses of 10 or 20 mg/kg/day in 0.1 mL of super-refined sesame oil (Corda, Inc., Parisppany, NJ). Tumors were measured with calipers thrice weekly, and tumor volumes were calculated using the formula: volume ) length × width × heigth. Animal weights were recorded thrice weekly, and clinical signs of overall health status and cutaneous toxicities were recorded weekly.
Receptor Expression. RNA was isolated using the QuickPrep Kit (Amershsam Pharmacia Biotech, Piscataway, NJ), and cDNA was synthesized with Superscript reverse transcriptase (GibcoBRL, Gaithersburg, MD) according to the manufacturer's instructions. The specific primers and annealing conditions used for the PCR reactions were previously described and demonstrated to be specific for the individual receptor subtypes. 41 The RXR expression was not evaluated because a human RXRγ gene has not been cloned. All PCR reactions were performed under the same conditions in a 50-µL reaction volume containing 5 µL of cDNA from reverse transcription, 1.25 U of Taq DNA polymerase, and the buffer provided. Initial denaturation was performed at 94°C for 5 min, followed by 35 cycles of 45 s at 94°C, 45 s at the indicated annealing temperature, and 1 min at 72°C with an ending of 1 5-min cycle at 72°C. Negative control reactions consisted of rt-PCR reactions without added RNA.
Receptor Activation. The CV-1 cells were plated in 6-well culture plates at a density of 7.5 × 10 4 cells/well and, after 24 h, were cotransfected with a retinoic acid receptor expression vector (pECE-hRARR, pECE-hRAR , pECE-hRARγ, pSG5-mRXRR, pSG5-mRXR , or pSG5-mRXRγ), a retinoic acid responsive reporter plasmid ( RARE-tk-CAT), and a transfection control plasmid (pJATLac) using FuGENE6 transfection reagent (Boehringer Mannheim Corp., Indianapolis, IN). The RARE-tkCAT plasmid contained the chloramphenicol acetyltransferase gene (CAT) driven by the thymidine kinase (tk) promoter and the RAR retinoic acid response element (RARE). The pJATLac plasmid contained the -galactosidase ( Gal) gene driven by the actin promoter. About 16-18 h after transfection, retinoids or DMSO (solvent) was added to the cells. The retinoids were administered at 10-fold dilutions of concentrations ranging from 10 -5 to 10 -10 M. The concentration of DMSO in all treated and control cultures was 0.01% which was not cytotoxic to the cells. After incubation for 24 h, cell lysates were prepared and assayed for reporter expression using CAT and Gal ELISA kits (Boehringer Mannheim Corp., Indianapolis, IN) according to the manufacturer's instructions. The CAT expression levels were corrected for transfection efficiency by dividing by the Gal expression levels. Each experiment was performed in triplicate and repeated at least twice.
Anti-AP-1 Activity. The SCC-2 cells were plated at 3 × 10 5 cells/well in 6-well plates 24 h before transfection. The cultures were cotransfected with a CAT reporter plasmid driven by the collagenase promoter (Col-CAT) and the pJATLac plasmid DNA using FuGENE6 transfection reagent (Boehringer Mannheim Corp., Indianapolis, IN) according to the manufacturer's instructions. After incubation for 24 h, the media was replenished, and retinoids were added at a concentration of 10 -5 M. After another 48 h, CAT and Gal expressions were quantitated as described above. All values were divided by the value of control cultures treated with DMSO to determine the percent activities. Each experiment was performed in duplicate and repeated twice.
